These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

743 related articles for article (PubMed ID: 25921130)

  • 1. Comparative Effectiveness of Risk-adapted Surveillance vs Retroperitoneal Lymph Node Dissection in Clinical Stage I Nonseminomatous Germ Cell Testicular Cancer: A Retrospective Follow-up Study of 81 Patients.
    Fan G; Zhang L; Yi L; Jiang ZQ; Ke Y; Wang XS; Xiong YY; Han WQ; Zhou X; Liu C; Yu X
    Asian Pac J Cancer Prev; 2015; 16(8):3267-72. PubMed ID: 25921130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].
    Liu ZW; Zhou FJ; Han H; Qin ZK; Yu SL; Li YH; Ye YL; Teng XY
    Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimizing treatment without compromising cure with primary surveillance for clinical stage I embryonal predominant nonseminomatous testicular cancer: a population based analysis from British Columbia.
    Al-Tourah AJ; Murray N; Coppin C; Kollmannsberger C; Man A; Chi KN
    J Urol; 2005 Dec; 174(6):2209-13, discussion 2213. PubMed ID: 16280765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of patients with clinical stage I nonseminomatous testicular germ cell tumours: active surveillance versus primary chemotherapy versus nerve sparing retroperitoneal lymphadenectomy.
    Heidenreich A; Pfister D
    Arch Esp Urol; 2012 Mar; 65(2):215-26. PubMed ID: 22414450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-chemotherapy retroperitoneal teratoma in nonseminomatous germ cell tumors: Do predictive factors exist? Results from a national multicenter study.
    Dusaud M; Malavaud B; Bayoud Y; Sebe P; Hoepffner JL; Salomon L; Houlgatte A; Pignot G; Rigaud J; Fléchon A; Pfister C; Rouprêt M; Soulié M; Méjean A; Durand X
    J Surg Oncol; 2016 Dec; 114(8):992-996. PubMed ID: 27859263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Outcome of Retroperitoneal Lymph Node Dissection after Chemotherapy in Patients with Pure Embryonal Carcinoma in the Orchiectomy Specimen.
    Dowling CM; Assel M; Musser JE; Meeks JJ; Sjoberg DD; Bosl G; Motzer R; Bajorin D; Feldman D; Carver BS; Sheinfeld J
    Urology; 2018 Apr; 114():133-138. PubMed ID: 29410311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of Recurrence for Clinical Stage I and II Patients With Teratoma Only at Primary Retroperitoneal Lymph Node Dissection.
    Liu NW; Cary C; Strine AC; Beck SD; Masterson TA; Bihrle R; Foster RS
    Urology; 2015 Nov; 86(5):981-4. PubMed ID: 26232690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Early Oncologic Effectiveness of Primary Robotic Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer.
    Pearce SM; Golan S; Gorin MA; Luckenbaugh AN; Williams SB; Ward JF; Montgomery JS; Hafez KS; Weizer AZ; Pierorazio PM; Allaf ME; Eggener SE
    Eur Urol; 2017 Mar; 71(3):476-482. PubMed ID: 27234998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical outcome of postchemotherapy retroperitoneal lymph node dissection and predicting retroperitoneal histology in advanced nonseminomatous germ cell tumours of the testis].
    Li XD; Guo SJ; Chen SL; Liu ZF; Dong P; Zhang ZL; Jiang LJ; Yao K; Li YH; Han H; Qin ZK; Liu ZW; Zhou FJ
    Zhonghua Wai Ke Za Zhi; 2017 Aug; 55(8):603-607. PubMed ID: 28789511
    [No Abstract]   [Full Text] [Related]  

  • 10. Long-term oncological outcome after post-chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour.
    Fléchon A; Tavernier E; Boyle H; Meeus P; Rivoire M; Droz JP
    BJU Int; 2010 Sep; 106(6):779-85. PubMed ID: 20089110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group.
    Albers P; Siener R; Krege S; Schmelz HU; Dieckmann KP; Heidenreich A; Kwasny P; Pechoel M; Lehmann J; Kliesch S; Köhrmann KU; Fimmers R; Weissbach L; Loy V; Wittekind C; Hartmann M;
    J Clin Oncol; 2008 Jun; 26(18):2966-72. PubMed ID: 18458040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Relapse of Clinical Stage I Nonseminomatous Germ Cell Tumors on Surveillance.
    Hamilton RJ; Nayan M; Anson-Cartwright L; Atenafu EG; Bedard PL; Hansen A; Chung P; Warde P; Sweet J; O'Malley M; Sturgeon J; Jewett MAS
    J Clin Oncol; 2019 Aug; 37(22):1919-1926. PubMed ID: 30802156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trans- and extraperitoneal retroperitoneal lymph node dissection (RPLND) in the treatment for nonseminomatous germ cell testicular tumors (NSGCT): a single Chinese center's retrospective analysis.
    Tong S; Chen M; Zu X; Li Y; He W; Lei Y; Liu W; Qi L
    Int Urol Nephrol; 2014 Feb; 46(2):363-9. PubMed ID: 23996573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for relapse in patients with clinical stage I testicular nonseminomatous germ cell tumors.
    Dong P; Liu ZW; Li XD; Li YH; Yao K; Wu S; Qin ZK; Han H; Zhou FJ
    Med Oncol; 2013 Mar; 30(1):494. PubMed ID: 23400963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical impact of residual extraretroperitoneal masses in patients with advanced nonseminomatous germ cell testicular cancer.
    Masterson TA; Shayegan B; Carver BS; Bajorin DF; Feldman DR; Motzer RJ; Bosl GJ; Sheinfeld J
    Urology; 2012 Jan; 79(1):156-9. PubMed ID: 22202548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of post-chemotherapy robot-assisted retroperitoneal lymph node dissection in testicular cancer: multi-institutional study.
    Abdul-Muhsin H; Rocco N; Navaratnam A; Woods M; L'Esperance J; Castle E; Stroup S
    World J Urol; 2021 Oct; 39(10):3833-3838. PubMed ID: 33959785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Long-term results of laparoscopic retroperitoneal lymph node dissection (RPLND) in low-stage nonseminomatous germ-cell testicular tumors (NSGCTT) performed by a senior surgeon: 1999-2003].
    Pizzocaro G; Schiavo M; Solima S; Vitellaro M; Biasoni N; Nicolai N
    Urologia; 2010; 77 Suppl 17():50-6. PubMed ID: 21308676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes in patients with stage I non-seminomatous germ cell cancer.
    Lv ZJ; Wu S; Dong P; Yao K; He YY; Gui YT; Zhou FJ; Liu ZW; Cai ZM
    Asian J Androl; 2013 Jul; 15(4):558-63. PubMed ID: 23685909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy analysis of three therapeutic modes on clinical stage Ia nonseminomatous germ cell testicular tumors].
    Dong P; Liu ZW; Li XD; Wu S; Li YH; Yao K; Qin ZK; Han H; Zhou FJ
    Zhonghua Wai Ke Za Zhi; 2013 Mar; 51(3):256-60. PubMed ID: 23859330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary Retroperitoneal Lymph Node Dissection for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumor-N1, N2, and N3 Disease: Is Adjuvant Chemotherapy Necessary?
    Tachibana I; Kern SQ; Douglawi A; Tong Y; Mahmoud M; Masterson TA; Adra N; Foster RS; Einhorn LH; Cary C
    J Clin Oncol; 2022 Nov; 40(32):3762-3769. PubMed ID: 35675585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.